Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis

被引:7
作者
Baron, Gabriel
Boutron, Isabelle
Giraudeau, Bruno
Ravaud, Philippe
机构
[1] INSERM, U738, Paris, France
[2] Univ Paris 07, UFR Med, Paris, France
[3] Hop Bichat Claude Bernard, AP HP, Dept Epidemiol Biostat & Rech Clin, F-75877 Paris, France
[4] INSERM, CIC 202, Tours, France
[5] CHRU Tours, CIC, Tours, France
关键词
D O I
10.1136/ard.2006.063164
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: Because an increasing number of clinical trials evaluating disease-modifying antirheumatic drugs in rheumatoid arthritis ( RA) emphasise radiographic outcomes as a primary outcome, using a reproducible radiographic measure should be placed at a premium. Aim: To evaluate the reporting of radiographic methods in randomised trials assessing radiographic outcomes in RA. Methods: Medline was searched for randomised controlled trials assessing radiographic outcomes published between January 1994 and December 2005 in general medical and specialty journals with a high impact factor. One reader extracted data ( radiographic acquisition, assessment and reproducibility) using a standardised form. Results: A total of 46 reports were included in the analysis. The mean (SD) methodological quality scores on the Jadad scale ( range 0-5) and the Delphi list (0-9) were 2.9 (1.2) and 6.4 (1.3), respectively. Use of a standardised procedure for the acquisition of the radiographs was reported in 2 (4.3%) articles. 2 ( 4.3%) reports indicated that the quality of the radiographs was evaluated. In 65.2% of the reports, >= 2 radiographic scores were used. Reporting of radiographic assessment was well detailed for number of readers (91.3%), information on readers ( 71.7%), blinding (91.4%) and how films were viewed (74.0%). The reproducibility of the reading was reported in 39.1% of the articles. Conclusion: The reporting of results of randomised controlled trials of radiographic outcomes in RA shows great variability in radiographic scores used. Reporting of radiographic methods could be improved upon, especially the acquisition procedure and the reproducibility of the reading.
引用
收藏
页码:651 / 657
页数:7
相关论文
共 91 条
[1]
The revised CONSORT statement for reporting randomized trials: Explanation and elaboration [J].
Altman, DG ;
Schulz, KF ;
Moher, D ;
Egger, M ;
Davidoff, F ;
Elbourne, D ;
Gotzsche, PC ;
Lang, T .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) :663-694
[2]
Violation of the intent-to-treat principle and rate of missing data in superiority trials assessing structural outcomes in rheumatic diseases [J].
Baron, G ;
Boutron, I ;
Giraudeau, B ;
Ravaud, P .
ARTHRITIS AND RHEUMATISM, 2005, 52 (06) :1858-1865
[3]
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[4]
Bluhm GB, 1997, J RHEUMATOL, V24, P1295
[5]
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [J].
Boers, M ;
Verhoeven, AC ;
Markusse, HM ;
vandeLaar, MAFJ ;
Westhovens, R ;
vanDenderen, JC ;
vanZeben, D ;
Dijkmans, BAC ;
Peeters, AJ ;
Jacobs, P ;
vandenBrink, HR ;
Schouten, HJA ;
vanderHeijde, DMFM ;
Boonen, A ;
vanderLinden, S .
LANCET, 1997, 350 (9074) :309-318
[6]
Prevention or retardation of joint damage in rheumatoid arthritis - Issues of definition, evaluation and interpretation of plain radiographs [J].
Boers, M ;
van der Heijde, DMFM .
DRUGS, 2002, 62 (12) :1717-1724
[7]
Boini S, 2001, ANN RHEUM DIS, V60, P817
[8]
Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO
[9]
2-2
[10]
USE OF THE RADIOGRAPH TO MEASURE THE COURSE OF RHEUMATOID-ARTHRITIS - THE GOLD STANDARD VERSUS FOOLS GOLD [J].
BROWER, AC .
ARTHRITIS AND RHEUMATISM, 1990, 33 (03) :316-324